OncoNano Medicine Announces Presentation at AACR-NIC-EORTC International Conference on Molecular Targets and Cancer Therapeutics
News > Health News
Audio By Carbonatix
6:00 AM on Wednesday, October 15
The Associated Press
DALLAS--(BUSINESS WIRE)--Oct 15, 2025--
OncoNano Medicine, Inc. (“OncoNano”) today announced a late-breaking research poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Boston, Massachusetts, October 22 - 26, 2025. Details on the posters are below.
Presentation Details
Title: | Results from part-1 of ON-5001: a multi-center, dose escalation and dose finding Phase 1 trial of ONM-501, a dual-acting STING agonist, alone or in combination with cemiplimab in patients with solid tumors and lymphoma |
| Session: | Poster Session A |
| Date & Time: | Thursday, October 23, 12:30-4 pm |
About ONM-501
ONM-501 is a dual-activating agonist of the stimulator of interferon gene (“STING”) pathway composed of cGAMP (the endogenous activator of STING) linked to a proprietary pH-activated polymer (the OMNI™ polymer). ONM-501 is presently being studied in a Phase 1 clinical trial (ON-5001). In preclinical models, the dual activation of STING by ONM-501has been shown to lead to direct anti-tumor effect, as well as leading to an anti-tumor immune response over an extended period of time. Development of ONM-501 was funded in part by the Cancer Prevention and Research Institute of Texas.
About OncoNano Medicine
OncoNano Medicine, Inc. is a clinical-stage biotechnology company working to transform cancer therapeutics with its proprietary nanotechnology platform. OncoNano's polymeric micelle platform is designed to leverage a universal tumor target, namely pH, to precisely deliver anti-cancer payloads to the tumor microenvironment. Our product candidates are designed to improve the pharmacokinetic and pharmacodynamic properties of various payloads from small molecules to large biologics through encapsulation and localized tumor targeting. OncoNano is utilizing its polymeric micelle technology to generate a robust oncology pipeline to support novel therapeutic development for patients with high unmet medical needs. Learn more about our platform and pipeline at www.OncoNano.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20251015455065/en/
CONTACT: OncoNano Medicine
LA Communications
Lauren Arnold
617-694-5387
Lauren@LACommunications.net
KEYWORD: TEXAS MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH ONCOLOGY CLINICAL TRIALS
SOURCE: OncoNano Medicine, Inc.
Copyright Business Wire 2025.
PUB: 10/15/2025 07:00 AM/DISC: 10/15/2025 06:59 AM
http://www.businesswire.com/news/home/20251015455065/en
